Waldemar Debinski to Recombinant Proteins
This is a "connection" page, showing publications Waldemar Debinski has written about Recombinant Proteins.
Connection Strength
0.316
-
Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol. 2012 Aug; 32(16):3253-64.
Score: 0.103
-
Mintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, Debinski W. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm. 2008 Oct; 23(5):581-9.
Score: 0.080
-
Mintz A, Gibo DM, Madhankumar AB, Debinski W. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J Neurooncol. 2003 Aug-Sep; 64(1-2):117-23.
Score: 0.056
-
Madhankumar AB, Mintz A, Debinski W. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem. 2002 Nov 08; 277(45):43194-205.
Score: 0.052
-
Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Ra2 tumor-restricted biomarker. Neuro Oncol. 2012 Oct; 14(10):1239-53.
Score: 0.026